Short Summary
The suit was filed by Novartis seeking permanent injunction against infringement of its patent IN'026. Natco Pharma sought leave to file an additional written statement, arguing that plaintiffs suppressed documents relating to a prior Divisional Application which led to the grant of the patent. The Court allowed the application, holding that Order VIII Rule 9 CPC grants wide discretion to allow such pleadings in the interest of justice.
Detailed Summary
The suit was filed by Novartis seeking permanent injunction against infringement of its patent IN'026. Natco Pharma sought leave to file an additional written statement, arguing that plaintiffs suppressed documents relating to a prior Divisional Application which led to the grant of the patent. The Court allowed the application, holding that Order VIII Rule 9 CPC grants wide discretion to allow such pleadings in the interest of justice.
Practitioner Note
This case demonstrates the evidentiary and procedural standards applied in patent matters before Delhi High Court. Understanding the court's reasoning in Novartis Ag vs Natco Pharma Limited is valuable context for structuring arguments or assessing risk in similar proceedings.
Related Cases
Novartis AgvsMsn Laboratories Pvt Ltd
The plaintiff alleges that the defendant infringed its patent by launching a product containing Eltrombopag Olamine without a license. The court granted an ex parte injunction against the defendant's product 'REBOPAG'.
The Trustees Of Columbia UniversityvsThe Assistant Controller of Patents and Designs
The appellant challenged an order rejecting its amended patent claims (1-19) for 'METHODS AND COMPOSITIONS FOR TREATMENT OF AMYLOID DEPOSITION DISEASES' under Section 59 of the Patents Act. The appellant argued that the amendments were supported by the complete specification, citing relevant case law. The High Court set aside the impugned order and remanded the matter for fresh reconsideration.
F.Hoffmann-La Roche AgvsAssistant Controller of Patents and Designs, Government of India
F.Hoffmann-La Roche Ag appealed an order rejecting its patent application for a subcutaneous anti-HER2 antibody formulation. The rejection was based on the product lacking inventive step and being known in the market. The court allowed the appeal, noting that the original decision failed to address 11 out of 12 claims independently.
Nayan India Science And Technologies Private LimitedvsIntents Mobi Private Limited & Anr
The plaintiff filed a suit alleging infringement of three Indian Patents (373372, 407425, and 317629) by the defendant. The court registered the plaint as a suit and directed parties to file pleadings while addressing applications for injunctions.
Sicpa Holding SavsThe Controller of Patents
Sicpa Holding Sa appealed the rejection of its patent application for 'Inline Spectroscopic Reader and Methods' by the Controller of Patents, which cited a lack of inventive step. The High Court found that the Controller had not adequately considered the detailed explanations provided by the appellant in response to the objections raised on prior art. Consequently, the appeal was allowed, and the matter was remanded for fresh consideration.
Dealing with a patent challenge?
Whether it's a Section 3(d) rejection, a post-grant opposition, or a FRAND dispute, Arctic's patent litigation team has handled it. Get a strategy call.
Disclaimer: This page contains an automated summary based on publicly available judicial records. The content is generated for informational purposes only and does not constitute legal advice. Always verify details against the original source judgment before relying on this information for any legal purpose. If you believe any information is inaccurate, please contact us.